Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 13/20 | 0.62 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.62 |
| ▸ | EHMT1 | Q9H9B1 | 10/20 | 0.49 |
| ▸ | SPIN1 | Q9Y657 | 4/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.47 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL20303875 | 1.00 | EHMT2 (0.62) | EHMT2DNMT1EHMT1SPIN1TLR9 | |
| SCHEMBL20351127 | 0.95 | EHMT2 (0.65) | EHMT2DNMT1EHMT1SPIN1 | |
| Formic Acid SCHEMBL19260658 | 0.87 | EHMT2 (0.55) | EHMT2DNMT1EHMT1SPIN1TLR9 | |
| SCHEMBL20347557 | 0.86 | EHMT2 (0.55) | EHMT2DNMT1EHMT1SPIN1 | |
| SCHEMBL20303994 | 0.86 | EHMT2 (0.67) | EHMT2DNMT1EHMT1SPIN1TLR9 | |
| Formic Acid SCHEMBL20336805 | 0.83 | EHMT2 (0.50) | EHMT2DNMT1EHMT1SPIN1TLR9 | |
| Formic Acid SCHEMBL20303978 | 0.82 | SPIN1 (0.51) | EHMT2DNMT1EHMT1SPIN1TLR9 | |
| SCHEMBL20304028 | 0.81 | EHMT2 (0.73) | EHMT2DNMT1EHMT1SPIN1TLR9 | |
| SCHEMBL20720603 | 0.81 | EHMT2 (0.58) | EHMT2DNMT1EHMT1SPIN1TLR9 | |
| Formic Acid SCHEMBL20336801 | 0.81 | SPIN1 (0.51) | EHMT2DNMT1EHMT1SPIN1TLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713299-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| EP-4063358-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713299-B2 | Histone methyltransferase inhibitors | EHMT1, DOT1L, EHMT2 | EHMT2 3/4885DNMT1 95/4885EHMT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.